Dr. Vikas Sukhatme has plenty of ideas on how to improve cancer therapy.
And they all revolve around repurposing inexpensive, generic drugs that show real scientific promise in extending the lives of cancer patients.
But here’s the catch: Sukhatme, who is the chief academic officer at Harvard-affiliated Beth Israel Deaconess Medical Center, wants to do it for no profit. And because of that, he hasn’t been able to raise the sufficient funding to launch the clinical trials to validate these drugs that are currently just used off-label.
About the Author Reprints
